Abstract
TP53 is the most frequently mutated gene in cancer. We developed a molecular signature detecting underlying TP53 alterations. This signature identified aggressive tumors, and after adjusting for known predictors of worse outcomes, the signature identified patients with prostate cancer likely to develop metastases. These findings may help doctors identify patients with prostate cancer with aggressive tumors and hence, choose the optimal treatment.
Original language | English (US) |
---|---|
Journal | Clinical Genitourinary Cancer |
DOIs | |
State | Accepted/In press - 2020 |
Keywords
- Biologic signature
- Genomic classifier
- Risk stratification
- TCGA prostate
- TP53 gene
ASJC Scopus subject areas
- Oncology
- Urology